
Pfizer has invested $25 million in Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases, …

Vedanta Biosciences, a company developing therapies designed to modulate the human microbiome, has appointed former Genzyme group vice president, Bruce …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

